Abstract
Atherothrombosis-related diseases are one of the world’s leading causes of mortality, and thus the search for new therapeutic approaches in this area remains a very urgent task. Modern pharmacogenomic technologies make it possible to obtain valuable data on disease pathogenesis and optimal therapeutic approaches. One promising research direction is the study of the thromboxane A2 - thromboxane A synthase - thromboxane A2 receptor axis. This review summarizes the recent evidence and suggests that systematic works in this area are creating new and promising opportunities in the treatment of patients with cardiovascular diseases.
Keywords: Inhibitors of thromboxane A2-synthase, pharmacogenetics, thromboxane A synthase, thromboxane, cardiovascular diseases, prostaglandins.
Graphical Abstract
155
10
1
1